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Abstract
Background: Use of estrogen with progestin (combination therapy) is associated with increased incidence of estrogen 
receptor–positive (ER+) breast cancer in observational studies and randomized trials among postmenopausal white women. 
Whether this is also the case among African American women is not established.
Methods: Using data from the AMBER consortium collected from 1993 to 2013, we assessed use of estrogen alone and 
of combination therapy in relation to ER+ and ER-negative (ER-) breast cancer risk in postmenopausal African American 
women, based on 1132 ER+ case patients, 512 ER- case patients, and 6693 control patients. Odds ratios (ORs) and confidence 
intervals (CIs) were estimated using multinomial logistic regression with control for breast cancer risk factors.
Results: Forty-seven percent of control patients had used estrogen alone, combination therapy, or both. The odds ratio for 
ER+ breast cancer associated with combination use, relative to never use of either estrogen alone or combination therapy, 
was 1.50 (95% CI = 1.25 to 1.79). The increase was greater for recent (OR = 1.55, 95% CI = 1.21 to 1.99) and long-term use 
(OR = 1.75, 95% CI = 1.13 to 2.73) and among nonobese women (OR = 1.91, 95% CI = 1.29 to 2.83). Breast cancer risk was 
increased regardless of the interval between onset of menopause and initiation of combination use (OR = 1.43, 95% CI = 1.11 
to 1.85, for <5 year interval; OR = 1.78, 95% CI = 1.34 to 2.37, for ≥5 year interval). Combination use was not associated with 
risk of ER- breast cancer, and use of estrogen alone was not associated with risk of either ER+ or ER- breast cancer.
Conclusion: Use of estrogen with progestin increases risk of ER+ breast cancer in African American women. A decrease in 
use would be expected to reduce the number of ER+ cancers.
Observational studies (1–9) and randomized trials (10–12) indi-
cate that use of supplements of estrogen together with pro-
gestin (“combination” use) increases the incidence of breast 
cancer, largely estrogen receptor–positive (ER+) cancer, among 
white postmenopausal women. The increase declines after 
cessation of use (1,7,13), but how long it persists is unclear (6). 
Users of estrogen alone in the Women’s Health Initiative (WHI) 
randomized trial had a lower incidence of breast cancer than 
nonusers (14), but some observational studies suggest that long-
term use increases risk (1,7,15). The relative increase in risk 
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associated with female hormone use has been greater among 
leaner women in some studies (1,7,9,16,17). The timing of use 
in relation to onset of menopause may also modify an effect: In 
WHI (12) and the British Million Women’s follow-up study (18), 
the increase in risk was greater for use begun within five years 
of onset of menopause than for use begun later.
Only a few studies have assessed African American women 
specifically. In the Black Women’s Health Study (BWHS), estro-
gen alone and combination use were associated with increased 
breast cancer incidence (19). In the Nashville Breast Health 
Study (20), a follow-up study based on mammography registries 
(17), and the Carolina Breast Cancer Study (CBCS) (21), hormone 
use was not associated with increased risk of breast cancer 
among African American women, but all types of hormone use 
were grouped together, limiting interpretation of the findings. In 
a multicenter case-control study of white and African American 
women, continuous combined estrogen with progestin was 
associated with increased risk while estrogen alone was not, 
and race reportedly did not modify the associations (22).
To assess estrogen alone and combination use in relation to 
ER+ and ER- cancer in African American women and the potential 
modifying effects of body mass index and timing of use relative to 
menopause onset, we analyzed data from the African American 
Breast Cancer Epidemiology and Risk (AMBER) Consortium (23).
Methods
Participating Studies
The AMBER Consortium pools data from four studies of breast 
cancer subtypes in African American women (23). The BWHS is a 
cohort study of 59 000 African American women age 21 to 69 years 
at baseline in 1995, followed through biennial health question-
naires (19). Incident breast cancer were self-reported; case 
patients were confirmed by pathology data from hospitals and 
from cancer registries in 24 states covering 95% of participants. 
A nested case-control dataset was created: For each case patient, 
control patients selected from BWHS participants who had not 
developed breast cancer at the case patient’s diagnosis date (index 
date) were matched on five-year age group, geographic region, 
and most recent questionnaire completed before the index date. 
The CBCS is a population-based case-control study of breast can-
cer among women age 20 to 74 years in North Carolina (24); we 
used data collected from 1993 to 2011. Case patients were iden-
tified through the North Carolina Central Cancer Registry, with 
oversampling of younger and African American case patients. 
Control patients younger than age 65  years, identified from 
Division of Motor Vehicle lists, and older control patients, identi-
fied from Health Care Financing Administration lists, were fre-
quency-matched to case patients on race and five-year age group. 
Exposure and covariate data with reference to the year before 
diagnosis (case patients) or interview date (control patients) were 
collected through in-person interviews. The Multiethnic Cohort 
Study (MEC) is a prospective study that included 16 594 African 
American women age 45 to 75 years at baseline from 1993 to 1996 
(25). Participants were identified through driver’s license files 
for Hawaii and Los Angeles County in California. Case patients 
were ascertained through the Hawaii Tumor Registry, Cancer 
Surveillance Program for Los Angeles County, and California 
State Cancer Registry. A  nested case-control dataset was cre-
ated: Case patients were matched with control patients accord-
ing to five-year age group and questionnaire completed before 
the case diagnosis. The Women’s Circle of Health Study (WCHS) 
is a case-control study begun in 2003 of women age 20 to 75 years 
in New York and New Jersey (26,27). Breast cancer case patients 
were identified through major hospitals in New York and the New 
Jersey Cancer Registry. Control patients were identified through 
random digit dialing and community-based recruitment and 
were frequency matched to case patients on five-year age group. 
Exposure and covariate data were collected through in-person 
interviews with reference to the year before diagnosis (cases 
patient) or interview date (control patients). Each study obtained 
informed consent and was approved by the relevant institutional 
review boards. The data from the two case-control studies and 
the nested case-control datasets from the follow-up studies were 
harmonized and pooled at the AMBER Consortium’s data coordi-
nating center with input from each study.
Study Population
The present study was based on data collected between 1993 
and 2013 from women age 40 to 75  years who reported their 
periods had stopped because of natural causes for at least a year 
or because of surgery (hysterectomy with bilateral oophorec-
tomy or bilateral oophorectomy alone).
Case Patients
Potential case patients were incident cases of invasive 
breast cancer (91.4%) or ductal carcinoma in situ (8.6%). 
Immunohistochemistry data from hospital and cancer registry 
records were used to classify case patients as ER+ or ER- (73.7% 
of potential case patients). When human epidermal growth fac-
tor receptor 2 (HER2) data were available for ER- case patients 
(61.7%), they were classified according to triple-negative status 
(TN: ER-, PR-, HER2-). The distribution of case patients by subtype 
(Table 1) was as expected for African American women (28–31).
Exposure and Covariate Data
Each study asked about menopause, female hormone use for 
menopause, types of hormones used, age started, and duration. 
Information on breast cancer risk factors included breast cancer 
in mother, sister, or daughter, reproductive factors, weight, edu-
cation, and use of oral contraceptives, alcohol, and cigarettes.
Data Analysis
We used multinomial logistic regression models to calculate 
odds ratios (ORs) and confidence intervals (CIs) for the relation 
of estrogen alone and combination use to risk of ER+ and ER- 
breast cancer; the reference category was never use of either 
estrogen alone or combination therapy. We controlled for five-
year age group, study, index date (continuous), geographic 
region (New Jersey, other Northeast, South, Midwest, West), edu-
cational attainment (<12, 12, 13–15, 16, >16 years), family history 
of breast cancer (yes, no), age at menarche (<11, 11–12, 13–14, 
15–16, ≥17), parity (nulliparous, parous), age at first birth (<25, 
≥25), age at menopause (<45, 45–49, 50–54, ≥55), type of meno-
pause (natural menopause, bilateral oophorectomy), body mass 
index (<25, 25–29, ≥30 kg/m2), alcohol consumption (current, 
other), and cigarette smoking (<10, ≥10 pack-years). Control for 
lactation and mammography use did not alter the estimates. We 
used indicator variables for missing data (<2% for each variable). 
Effect modification was assessed in strata of age, body mass 
index, type of menopause, and interval between menopause 
and female hormone initiation; interaction on the multiplicative 
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scale was tested by the likelihood ratio test, comparing models 
with and without interaction terms. Statistical tests were two-
sided. SAS 9.2 statistical software (SAS Institute Inc., Cary, NC) 
was used. A P value of less than .05 was considered statistically 
significant.
Results
There were 1132 ER+ case patients, 512 ER- case patients (includ-
ing 219 TN), and 6693 control patients. Among the control 
patients, 47.6% had used some form of hormone therapy: 28.3% 
used estrogen alone, 12.9% used combination therapy, and 6.4% 
used both. Combination use was lower in CBCS and WCHS than 
in BWHS and MEC (Table 1), and use of estrogen alone or com-
bination therapy in the previous five years was lowest in MEC.
For ER+ breast cancer, odds ratios for ever use of estrogen 
alone, use within the previous five years, and use lasting 10 years 
or more were close to the null (Table 2). The odds ratio for use 
lasting 20 years or more was 1.20 (95% CI = 0.73 to 1.96), and the 
odds ratio for such use that continued until less than five years 
previously was 0.69 (95% CI = 0.33 to 1.43) (data not shown). For 
ER- breast cancer, odds ratios for estrogen alone were compati-
ble with the null (Table 2). For TN cancer, the odds ratio for use of 
estrogen alone was 1.14 (95% CI = 0.77 to 1.69) (data not shown).
Combination use was associated with increased risk of ER+ 
cancer, with an odds ratio of 1.50 (95% CI = 1.25 to 1.79) for ever 
use (Table 2). Risk increased with duration of use to 1.75 (95% 
CI = 1.13 to 2.73) for 10 years or more. Ten or more years after 
cessation, the odds ratio for ever use was 1.34 (95% CI = 0.99 to 
1.82); the decline following cessation was not monotonic, as the 
odds ratio for last use five to nine years ago, 1.80 (95% CI = 1.32 to 
2.45), was greater than the odds ratio, 1.55 (95% CI = 1.21 to 1.99), 
for last use less than five years previously. Use of combination 
therapy was not associated with increased risk of ER- cancer 
(Table 2). For TN cancer, the odds ratio for combination use was 
1.32 (95% CI = 0.88 to 1.98), and estimates for last use less than 
five years previously and duration of use 10 or more years were 
also compatible with the null (data not shown). Control for dura-
tion of use in analyses of time since last use, time since last use 
in analyses of duration, and use of estrogen alone resulted in 
little change in the odds ratios for combination use. The results 
were unchanged when in situ cases were excluded.
As shown in Table 3, the odds ratio of ER+ cancer associated 
with combination use was most increased among leaner women 
(BMI < 25 kg/m2, OR = 1.91, 95% CI = 1.29 to 2.83), less increased 
among overweight women (BMI  =  25–29 kg/m2, OR  =  1.69, 95% 
CI = 0.83 to 1.64), and closest to the null among obese women 
(BMI ≥ 30 kg/m2, OR = 1.24, 95% CI = 0.93 to 1.64) (Pinteraction = .17). 
Within strata of age (Table  3), the odds ratios for combina-
tion use were elevated among women age 60 to 69  years and 
70  years or older but not among women age 40 to 59  years 
(Pinteraction = .58). In subanalyses among women age 40 to 59 years, 
the odds ratios for combination use were elevated among 
leaner women (OR = 2.17, 95% CI = 1.05 to 4.46) and overweight 
women (OR = 1.69, 95% CI = 1.23 to 2.31) but not among obese 
women (OR =1.24, 95% CI = 0.93 to 1.65) (data not shown). The 
odds ratios for combination use were increased approximately 
50% among women menopausal because of natural causes and 
among women menopausal because of bilateral oophorectomy 
(Pinteraction = .82) (Table 3).
A statistically significant increase in risk of ER+ cancer associ-
ated with combination use was observed regardless of the inter-
val between onset of menopause and initiation of use (Table 4): 
Odds ratios were 1.43 (95% CI = 1.11 to 1.85) for intervals of less 
than five years and 1.78 (95% CI = 1.34 to 2.37) for longer inter-
vals. There were no increases in ER- cancer risk for combination 
use regardless of timing of initiation, nor were there increases in 
risk of ER+ or ER- cancer associated with use of estrogen alone.
Results for combination use were similar in the two studies 
that included most users: The odds ratio for ER+ cancer associ-
ated with ever use was 1.64 (95% CI = 1.25 to 2.16) in BWHS and 
1.58 (95% CI = 1.18 to 2.12) in MEC.
Discussion
The present study indicates that an appreciable proportion of 
African American women have used menopausal female hor-
mone supplements: 47.6% of control patients in our four stud-
ies conducted in several areas of the United States from 1993 to 
2013 reported use. The lower use of female hormones in CBCS, a 
study whose participants had lower educational levels, reflects 
that women of higher socioeconomic status tend to more com-
monly use these drugs (32). The low prevalence of use in WCHS, 
a study initiated in 2003, reflects the nationwide decline in use 
following publication of results from WHI documenting higher 
breast cancer risk in users of combination therapy (11,33–35).
Based on data collected prospectively in two follow-up stud-
ies and data from two case-control studies, we found that use 
of estrogen with progestin is associated with increased risk of 
ER+ cancer in African American women. This finding agrees 
with results from the WHI randomized trial of combination use 
(11) and case-control (1,4,5) and follow-up studies (1–3,7–9) that 
were based largely on white women. In the E3N follow-up study 
in France, estrogen taken with a progestagen other than dydro-
gesterone was associated with increased breast cancer risk (36); 
the high-risk progestin category included medroxyprogester-
one acetate, which is widely used in the United States (9). As 
in many previous studies, we also found that breast cancer risk 
was greater for more recent and long-term use and that there 
was little evidence of an association of combination use with 
risk of ER- cancer (1–5,7–9).
In the WHI randomized trial, a statistically significant 
increased risk of breast cancer was observed for participants 
in the combination use group relative to the placebo group up 
to more than eight years following the end of the intervention 
study (11,37,38). In the Million Women’s follow-up study (7), risk 
declined within a few years after cessation of hormone use, but 
risk after cessation was not assessed for past use of estrogen 
alone and combination therapy separately. Risk of breast can-
cer associated with combination use was still increased 10 years 
after cessation in the present study, and the increased incidence 
for women in the E3N study with at least five years of use per-
sisted for up to 10 years after cessation (6).
The few studies that have assessed a potential modifying 
effect of timing of use in relation to onset of menopause on the 
association with combination use yielded differing results. In 
the present study, combination use was associated with a sta-
tistically significant increased risk of ER+ breast cancer regard-
less of when use began, and the odds ratio for use begun close 
to menopause was smaller than that for use begun later. In con-
trast, the Million Women’s Study (18) and WHI (12) found that 
combination use begun within five years of menopause onset 
increased risk of breast cancer appreciably more than use begun 
later. The E3N follow-up study’s results were mixed: There were 
increases in risk of similar magnitude for women who had used 
combination therapy for at least two years regardless of when 
use started, but for shorter-term users the risk estimate was 
greater for use that began within three years of menopause (36).
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In several large follow-up studies, associations of female hor-
mone use with increased risk of breast cancer were strongest 
among lean women and weakest among obese women (1,9,16–
18). In the present study, the increase in the odds ratio for ER+ 
cancer associated with combination use was also largest among 
the leaner women and smallest among obese women. In the 
WHI randomized trial (39), the hazard ratio for combination use 
was 1.29 (95% CI = 0.94 to 1.79) in lean women, 1.34 (95% CI = 1.04 
to 1.75) in overweight women, and 1.14 (95% CI = 0.90 to 1.44) 
in obese women. While not entirely consistent with the obser-
vational data, the WHI results are consistent with a smaller 
effect in obese women. If an effect is indeed smaller in obese 
women, it may reflect that the relative contribution of female 
hormone supplements to endogenous estrogen levels from body 
fat among postmenopausal obese women may be small in com-
parison with the relative contribution among thinner women, 
making it difficult to detect an increased risk because of hor-
mone use among heavier women.
The incidence of breast cancer, especially ER+ cancer, 
declined in the United States in 2002 and 2003, a decrease that 
has been attributed to the decline in use of combination ther-
apy that followed publicity about the WHI results (35,40,41). The 
rapid decline suggests that combination use promotes already-
existing cancers. However, the association with longer-duration 
use is compatible with a carcinogenic initiating effect (39).
Results on the association of use of estrogen alone with 
breast cancer risk differ among the various studies. Among 
women assigned to estrogen alone in the WHI randomized trial, 
incidence of breast cancer was 23% lower than in the placebo 
group (14); the statistically significant decreased incidence 
among users persisted several years post trial (42) but was no 
longer present when follow-up after the end of the trial had 
continued for more than eight years (38). In the present study, 
use of estrogen alone, even for durations up to 20 years among 
recent users, was not associated with risk of breast cancer. In 
the Nurses’ Health Study, a 50% increase in risk of ER+ cancer 
associated with current estrogen use became apparent after 
15 years of use (15), and an increase of more than 20% in over-
all breast cancer risk was found for more than 15 years of use 
in a case-control study in Los Angeles (5). In the collaborative 
analysis published in 1997 (1) and the Million Women’s Study 
(7), current long-term use of estrogen alone was also associated 
with increases in risk of breast cancer.
The WHI and observational studies of hormone use and 
breast cancer have answered somewhat different questions. 
The WHI assessed a combination regimen and an estrogen 
regimen that were commonly used in the United States, and 
the participants randomly assigned to these treatments or 
placebo were in their 50s, 60s, and 70s. The observational stud-
ies assessed whatever preparations study participants had 
chosen to use, and most women had begun use at the time 
of menopause. Well-conducted randomized trials and obser-
vational studies have different strengths and limitations (43). 
Case-control studies are susceptible to selection and report-
ing bias related to female hormone use, and follow-up studies 
are susceptible to selection bias related to female hormone 
use. Random assignment eliminates these biases, and stand-
ardized and thorough follow-up, as in WHI, minimizes biases 
related to case ascertainment. The WHI had sufficient statisti-
cal power to assess whether incidence of several conditions 
differed between treated women and the placebo group but 
was not well-powered to assess incidence within smaller sub-
groups. The large observational studies have had sufficient 
statistical power for assessment of hormone effects within 
subgroups, and they have been able to assess much longer 
durations of use than the WHI. Despite differences in design 
and populations, the WHI and observational studies are in 
agreement that certain regimens of combination use increase 
the risk of breast cancer and that the risk remains elevated for 
some time after use ceases. Results on estrogen alone, which 
likely has a smaller effect if any than combination use (1–9), 
have been variable. After the end of the WHI estrogen alone 
randomized trial, a decreased risk of breast cancer in users 
noted at the end of the intervention phase (14) had disap-
peared after longer follow-up (38,42). The observational study 
results have varied from no association to positive associa-
tions (1–9), but a large control study (5) and a large follow-up 
study (15) suggest that risk increases only after 15 to 20 years 
of use. Additional data on estrogen use for very long durations 
and other unsettled questions, such as whether the timing of 
use in relation to menopause matters, will come from obser-
vational studies. Judgements about the totality of the evidence 
Table 3. Use of estrogen plus progestin in relation to ER+ breast cancer, postmenopausal women age ≥40 y, stratified by body mass index, age, 
and type of menopause
Characteristic
Never used* Ever used
P†
Case patients/ 
Control patients OR (95% CI) ‡
Case patients/ 
Control patients OR (95% CI) ‡
Body mass index, kg/m2 .17
 <25 98/721 1.00 (referent) 62/317 1.91 (1.29 to 2.83)
 25–29 192/1179 1.00 (referent) 83/448 1.69 (0.83 to 1.64)
 ≥30 326/1501 1.00 (referent) 86/501 1.24 (0.93 to 1.65)
Age, y .58
 40–59 218/1147 1.00 (referent) 75/510 1.29 (0.93 to 1.78)
 60–69 228/1199 1.00 (referent) 101/516 1.60 (1.19 to 2.15)
 ≥70 203/1163 1.00 (referent) 59/267 1.72 (1.22 to 2.44)
Type of menopause
 Natural 521/2779 1.00 (referent) 178/942 1.55 (1.26 to 1.91)
 Bilateral oophorectomy 77/510 1.00 (referent) 48/302 1.51 (0.98 to 2.31) .82
* Never used estrogen alone or estrogen plus progestin. CI = confidence interval; OR = odds ratio.
† Two-sided P value for interaction.
‡ Adjusted for age, study, year, geographic region, education, parity, age at first birth, age at menopause, type of menopause, age at menarche, body mass index, oral 
contraceptive use, family history of breast cancer, alcohol use, and smoking.
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will need to weigh the quality of the studies and their statisti-
cal power.
Our study is the largest to date of female hormone supple-
ments and breast cancer risk in African American women and 
the first to informatively assess ER+ and ER- cancer separately 
in this group, but numbers in some subanalyses were small. 
While BWHS and CBCS published results on female hormones 
and breast cancer previously (19,21), the present analyses 
included larger numbers of users as well as participants from 
two other studies. However, our study is not without limitations. 
Classification of breast cancer subtype was based on results 
from numerous hospital pathology laboratories, which may 
have resulted in nondifferential misclassification of ER status. 
There will also have been misclassification of use of estrogen 
with progestin and estrogen alone because of errors in self-
report. However, self-report of female hormone use, especially of 
recent and long-duration use, has been found to be sufficiently 
accurate for use in epidemiologic studies (44). We lacked appro-
priate data for assessment of the dose and type of estrogen or 
progestin used.
In conclusion, our results provide strong evidence that com-
bination use is an important risk factor for ER+ cancer in African 
American women. It is well recognized that use of menopausal 
female hormone supplements was high among white women for 
many years, and the present data indicate that use has been com-
mon in postmenopausal African American women as well, although 
less so than among white women (9,17,21). As in white women, a 
reduction in combination use by African American women would 
be expected to reduce the number of ER+ breast cancers.
Funding
This research was funded by National Institutes of Health (P01 
CA151135, R01 CA058420, UM1 CA164974, R01 CA100598, UM1 
Table 4. Female hormone use in relation to breast cancer subtypes, postmenopausal women age ≥40 y, stratified by time between menopause 
and initiation of female hormone use
Time between menopause and 
initiation of female hormone use
ER+ ER-
Control patients Case patients OR (95% CI)* Case patients OR (95% CI)*
Never used† 3509 649  1.00 (referent) 300  1.00 (referent)
Estrogen alone
 <5-y interval
 Ever use 983 164  1.14 (0.90 to 1.45) 76  1.06 (0.75 to 1.49)
 Duration of use, y
  <5 611 97  1.16 (0.86 to 1.48) 36  0.85 (0.56 to 1.29)
  ≥5 358 66  1.18 (0.84 to 1.68) 38  1.45 (0.91 to 2.32)
 Time since last use, y
  <5 524 73  1.01 (0.72 to 1.41) 46  1.02 (0.66 to 1.58)
  ≥5 457 90  1.23 (0.93 to 1.64) 29  1.05 (0.67 to 1.65)
 ≥5-y interval
 Ever use 711 83 1.17 (0.87 to 1.56) 40 1.21 (0.80 to 1.82)
 Duration of use, y
  <5 468 56 1.12 (0.81 to 1.55) 32 1.34 (0.87 to 2.05)
  ≥5 211 25 1.38 (0.84 to 2.26) 6 0.70 (0.29 to 1.69)
 Time since last use, y
  <5 445 52 1.32 (0.92 to 1.91) 23 1.05 (0.63 to 1.76)
  ≥5 255 30 1.01 (0.66 to 1.53) 17 1.56 (0.90 to 2.71)
Estrogen plus progestin
 <5-y interval
 Ever use 568 988 1.43 (1.11 to 1.85) 28 0.69 (0.45 to 1.05)
 Duration of use, y
  <5 406 68 1.37 (1.02 to 1.84) 19 0.62 (0.38 to 1.03)
  ≥5 142 24 1.39 (0.87 to 2.23) 7 0.79 (0.36 to 1.75)
 Time since last use, y
  <5 313 47 1.33 (0.93 to 1.89) 17 0.65 (0.38 to 1.11)
  ≥5 254 51 1.54 (1.09 to 2.16) 11 0.75 (0.39 to 1.42)
 ≥5-y interval
 Ever use 412 78 1.78 (1.34 to 2.37) 23 1.15 (0.72 to 1.84)
 Duration of use, y
  <5 116 58 1.69 (1.23 to 2.33) 19 1.21 (0.73 to 2.02)
  ≥5 53 13 2.18 (1.14 to 4.17) 3 1.25 (0.38 to 4.14)
 Time since last use, y
  <5 203 36 1.72 (1.15 to 2.55) 13 1.15 (0.62 to 2.10)
  ≥5 207 42 1.86 (1.28 to 2.68) 10 1.16 (0.59 to 2.28)
* Adjusted for age, study, year, geographic region, education, parity, age at first birth, age at menopause, type of menopause, age at menarche, body mass index, oral 
contraceptive use, family history of breast cancer, alcohol use, and smoking. CI = confidence interval; OR = odds ratio.
† Never used estrogen alone or estrogen plus progestin.
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